Keyword: Ironwood Pharmaceuticals

heart

8. Praliciguat

Cyclerion Therapeutics was just a few months on from its spinout from Ironwood Pharma when it was forced to abandon a key indication for one of its lead drugs—soluble guanylate cyclase (sGC) stimulator praliciguat—prompting it to ax more than one-fifth of its workforce.